^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    IRAK-4 inhibitor

    Related drugs:
    7d
    A Study to Assess Adverse Events, Tolerability and How Single and Ascending Oral Doses of Nacresertib Move Through the Body In Healthy Adult Participants (clinicaltrials.gov)
    P1, N=93, Completed, AbbVie | Active, not recruiting --> Completed
    Trial completion • Adverse events
    1m
    CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer (clinicaltrials.gov)
    P1, N=43, Suspended, National Cancer Institute (NCI) | Recruiting --> Suspended
    Trial suspension
    |
    gemcitabine • albumin-bound paclitaxel • emavusertib (CA-4948)
    1m
    CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer (clinicaltrials.gov)
    P1, N=43, Recruiting, National Cancer Institute (NCI) | Trial completion date: Apr 2026 --> Apr 2027 | Trial primary completion date: Apr 2026 --> Apr 2027
    Trial completion date • Trial primary completion date
    |
    gemcitabine • albumin-bound paclitaxel • emavusertib (CA-4948)
    1m
    CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer (clinicaltrials.gov)
    P1, N=42, Recruiting, Washington University School of Medicine | Trial completion date: Jun 2028 --> Apr 2029 | Trial primary completion date: Sep 2027 --> Jul 2028
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 negative
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Herceptin (trastuzumab) • 5-fluorouracil • leucovorin calcium • emavusertib (CA-4948)
    2ms
    IRAK4: A Study to Evaluate the Effect of AZD6793 on the Pharmacokinetics and Pharmacodynamics of Metformin in Participants With Type 2 Diabetes Mellitus (clinicaltrials.gov)
    P1, N=28, Suspended, AstraZeneca | Recruiting --> Suspended
    Trial suspension
    |
    metformin
    2ms
    D7770C00001: A study of AZD2962, an IRAK4 inhibitor, in Participants with Haematologic Neoplasms (2025-520786-44-00)
    P1/2, N=7, Suspended, AstraZeneca AB | Recruiting --> Suspended
    Trial suspension
    2ms
    D7860C00005: A Double-blind, Placebo-controlled, Multiple-Dose, 2-Period Crossover Study to Evaluate the Effect of Steady-state AZD6793 on the Steady-state Pharmacokinetics/Pharmacodynamics of Metformin in Participants with Type 2 Diabetes Mellitus (2025-522551-25-00)
    P1, N=28, Suspended, AstraZeneca AB | Recruiting --> Suspended
    Trial suspension
    |
    metformin
    2ms
    Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer (clinicaltrials.gov)
    P1, N=48, Recruiting, Washington University School of Medicine | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cisplatin • Imfinzi (durvalumab) • gemcitabine • emavusertib (CA-4948)
    3ms
    CA-4948 102: Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) (clinicaltrials.gov)
    P1/2, N=366, Suspended, Curis, Inc. | Recruiting --> Suspended
    Trial suspension • IO biomarker
    |
    FLT3 (Fms-related tyrosine kinase 3) • SF3B1 (Splicing Factor 3b Subunit 1) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1)
    |
    FLT3 mutation • SF3B1 mutation
    |
    Venclexta (venetoclax) • emavusertib (CA-4948)
    3ms
    CA-4948-203: A Ph2 Study of Emavusertib + an Approved BTKi in Patients with CLL and Other B-cell Malignancies (2025-523600-68-00)
    P1/2, N=40, Not yet recruiting, Curis Inc.
    New P1/2 trial
    |
    clonoSEQ®
    |
    Brukinsa (zanubrutinib) • emavusertib (CA-4948)
    4ms
    CA-4948-104: A Ph1 Study of Emavusertib in AML CR MRD+ Patients Currently Receiving Azacitidine and Venetoclax (2023-505828-58-00)
    P1, N=24, Active, not recruiting, Curis Inc. | -> Active, not recruiting | Phase classification: PN/A --> P1
    Enrollment closed • Phase classification
    |
    Venclexta (venetoclax) • azacitidine • emavusertib (CA-4948)
    4ms
    IRAK4: A Study to Evaluate the Effect of AZD6793 on the Pharmacokinetics and Pharmacodynamics of Metformin in Participants With Type 2 Diabetes Mellitus (clinicaltrials.gov)
    P1, N=28, Recruiting, AstraZeneca
    New P1 trial
    |
    metformin